FindTrial
Sign In

To Evaluate the Vrana Ropana Action - wound healing action of Kadamba Ointment in the mangement of Grushta Vrana with special reference to Partial Thickness Abrassion.

A randomised open label controlled clinical study to evaluate the Vrana Ropana Action of Kadamba Ointment in the management of Ghrustha Vrana with special reference to Partial Thickness Abrasions. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/07/090246
Enrollment
30
Registered
2025-07-07
Start date
Unknown
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Dr Sneha Mysore
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects with classical symptoms of Ghrustha Vrana such as Osha, Srava, Vigatha Twak (partial thickness Abrasions- bleeding, pain, burning sensation and wounds with damage to epidermal and dermal layer of skin). 2. Subjects with wound of maximum size upto 10x20cm 3. Subjects aged between 21-70 years irrespective of gender, religion, occupation, economic status and educational status who is willing to give consent.

Exclusion criteria

Exclusion criteria: 1. Subjects presenting with chinna, bhinna, vidha and picchita vrana. 2. Subjects with Dusta vrana/ infected wounds/ diabetic wounds, osteomyelitis and gangrene. 3. Subjects suffering from infectious diseases like HIV, Hepatitis and tuberculosis or other sexually transmitted infections. 4. Subjects who are known cases of Leprosy, Syphilis, and Bleeding disorder. 5. Subjects suffering from immuno-compromised disorders.

Design outcomes

Primary

MeasureTime frame
Clinically significant healing of Ghrustha Vrana with with special reference to partial thickness abrasions assessed based on VAS scale, percentage of wound contraction, discharge, burning sensation and evaluation of floor of the wound for healthy granulation tissue. Timepoint: 1st, 3rd, 5th and 7th day.—

Secondary

MeasureTime frame
To improve the quality of life.[45] Generation of in depth analyzed data on the different aspect of the disease. Generation of data on possible unexpected drug reaction. Timepoint: 7th day & 14th day—

Countries

India

Contacts

Public ContactDr Sneha Mysore

Sri Sri College of Ayurvedic Science and Research Hospital

drpadmabhats@gmail.com9900410580

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026